IR-Med, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-15. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Yaniv Cohen, Chief Effective Officer, effective 2026-09-14
On September 14, 2026, the Board of Directors (the "Board") of IR-Med, Inc. (the "Company") appointed Yaniv Cohen, as interim Chief Effective Officer of the Company, effective as of September 14, 2026.
Find people with the same kind of experience as the Chief Effective Officer at IR-Med, Inc., with the record behind each one.
Find candidates like Chief Effective Officer at IR-Med, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time IR-Med, Inc. is in the news or changes leadership.
Get an alert when IR-Med, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for IR-Med, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.